(Q64184170)
Statements
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis (English)
0 references
April 2019
0 references
December 2021
0 references
60
0 references
18 year
0 references
100 year
0 references